Company / R&D per Share
Prime Medicine, Inc. R&D per Share History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.31
FY2024
5-year range
$1.13 / $5.44
FY2020-FY2024
Trend
-19.5%
vs FY2023
Sector context
#134 of 204
Health Care
What the data says
At $1.31, Prime Medicine, Inc.'s r&d per share ranks #134 of 204 in the Health Care sector. R&D per Share has declined for 3 consecutive years, from $5.44 in FY2021 to $1.31 in FY2024.
Based on SEC 10-K filings.
1.31 in FY2024 with a 3-year CAGR of -37.8%.
Declined from $2.56 to $1.31 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -37.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#134 of 204 in Health CareTop 66% of 204This company $1.31 Sector average $34.99
▼
-96.3% below sector average
Key checks
Key Insights
- Prime Medicine, Inc.'s r&d per share has declined for 3 consecutive years.
- In FY2024, r&d per share decreased 19.5% year-over-year.
- Ranks #134 out of 204 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.31 | -19.5% |
| FY2023 | $1.63 | -36.5% |
| FY2022 | $2.56 | -52.9% |
| FY2021 | $5.44 | +381.7% |
| FY2020 | $1.13 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026